Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
28 12 2021
28 12 2021
Historique:
received:
17
05
2021
accepted:
13
08
2021
pubmed:
1
10
2021
medline:
8
1
2022
entrez:
30
9
2021
Statut:
ppublish
Résumé
Peripheral T-cell lymphoma (PTCL) is a clinically aggressive disease, with a poor response to therapy and a low overall survival rate of approximately 30% after 5 years. We have analyzed a series of 105 cases with a diagnosis of PTCL using a customized NanoString platform (NanoString Technologies, Seattle, WA) that includes 208 genes associated with T-cell differentiation, oncogenes and tumor suppressor genes, deregulated pathways, and stromal cell subpopulations. A comparative analysis of the various histological types of PTCL (angioimmunoblastic T-cell lymphoma [AITL]; PTCL with T follicular helper [TFH] phenotype; PTCL not otherwise specified [NOS]) showed that specific sets of genes were associated with each of the diagnoses. These included TFH markers, cytotoxic markers, and genes whose expression was a surrogate for specific cellular subpopulations, including follicular dendritic cells, mast cells, and genes belonging to precise survival (NF-κB) and other pathways. Furthermore, the mutational profile was analyzed using a custom panel that targeted 62 genes in 76 cases distributed in AITL, PTCL-TFH, and PTCL-NOS. The main differences among the 3 nodal PTCL classes involved the RHOAG17V mutations (P < .0001), which were approximately twice as frequent in AITL (34.09%) as in PTCL-TFH (16.66%) cases but were not detected in PTCL-NOS. A multivariate analysis identified gene sets that allowed the series of cases to be stratified into different risk groups. This study supports and validates the current division of PTCL into these 3 categories, identifies sets of markers that can be used for a more precise diagnosis, and recognizes the expression of B-cell genes as an IPI-independent prognostic factor for AITL.
Identifiants
pubmed: 34592752
pii: 477109
doi: 10.1182/bloodadvances.2021005171
pmc: PMC8714715
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5588-5598Informations de copyright
© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Histopathology. 2012 Mar;60(4):570-85
pubmed: 22251198
Nat Genet. 2014 Apr;46(4):329-35
pubmed: 24531327
Am J Hematol. 2019 Jun;94(6):628-634
pubmed: 30829413
Blood. 2014 May 8;123(19):2915-23
pubmed: 24632715
J Clin Oncol. 2006 Jun 1;24(16):2472-9
pubmed: 16636342
Am J Surg Pathol. 2016 Mar;40(3):335-41
pubmed: 26574844
J Clin Invest. 2007 Mar;117(3):823-34
pubmed: 17304354
Blood. 2016 Sep 15;128(11):1490-502
pubmed: 27369867
Oncotarget. 2017 Nov 30;8(67):111386-111395
pubmed: 29340061
Leuk Lymphoma. 2016 Nov;57(11):2489-98
pubmed: 27347699
Haematologica. 2020 Jun;105(6):1582-1592
pubmed: 31488561
Oncotarget. 2018 Mar 1;9(22):16124-16133
pubmed: 29662631
Exp Hematol Oncol. 2021 Feb 5;10(1):9
pubmed: 33546774
Appl Immunohistochem Mol Morphol. 2019 Jul;27(6):416-422
pubmed: 29629950
Exp Hematol Oncol. 2021 May 14;10(1):33
pubmed: 33990228
Blood. 2008 May 1;111(9):4463-70
pubmed: 18292286
Eur J Haematol. 2007 Apr;78(4):290-6
pubmed: 17378891
Int Immunol. 2015 Aug;27(8):393-404
pubmed: 25920998
Nat Genet. 2014 Feb;46(2):171-5
pubmed: 24413737
Blood. 2014 May 1;123(18):2893-4
pubmed: 24786457
Br J Haematol. 2021 Jan;192(1):82-99
pubmed: 32426847
Cancer Treat Res. 2019;176:31-68
pubmed: 30596212
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Blood. 2019 Apr 11;133(15):1664-1676
pubmed: 30782609
J Clin Oncol. 2007 Aug 1;25(22):3321-9
pubmed: 17577022
Br J Haematol. 2018 Jun;181(6):760-769
pubmed: 29672827
J Clin Oncol. 2017 Jun 20;35(18):2008-2017
pubmed: 28459613
J Immunol. 2009 Oct 15;183(8):4994-5005
pubmed: 19801521
Blood. 2019 Dec 12;134(24):2159-2170
pubmed: 31562134